Sp477
NOVEL INSIGHTS INTO CELLULAR MECHANISMS OF CELIAC DISEASE AUTOIMMUNITY
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
While the immunology of celiac disease is considered well understood, there have been a number of important developments in recent years which improve our understanding of disease triggers, symptom presentation and treatment challenges and may provide insights into other immune mediated diseases. This session is planned as a mixed session with overviews of new concepts in cellular and cytokine manifestations of celiac disease followed by presentation of relevant abstracts.
While the immunology of celiac disease is considered well understood, there have been a number of important developments in recent years which improve our understanding of disease triggers, symptom presentation and treatment challenges and may provide insights into other immune mediated diseases. This session is planned as a mixed session with overviews of new concepts in cellular and cytokine manifestations of celiac disease followed by presentation of relevant abstracts.
Presenter
Tracks
Related Products
PANEL DISCUSSION
While the immunology of celiac disease is considered well understood, there have been a number of important developments in recent years which improve our understanding of disease triggers, symptom presentation and treatment challenges and may provide insights into other immune mediated diseases…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
